Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024. In the quarter to June 2026, revenue grew 13.0%, EPS fell 47.5%, free cash flow grew 28.9% and total debt rose 142.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

104.88 0.20 +0.19%
Market cap
$181.1B
P/E
33.9×
Fwd P/E
22.9×
Dividend yield
2.40%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100

Abbott Laboratories (ABT) Total debt

Alert me on Total debt

Abbott Laboratories's total debt at the end of fiscal 2025 was $12.9B, down 8.47% from $14.1B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $32.6B. Over the past ten years it has ranged from $5.9B (fiscal 2015) to $27.7B (fiscal 2017); the current reading is higher than 18% of that period. Abbott Laboratories ranks 1st of 147 Medical Devices companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2025 $12.9B (8.47%)
FY2024 $14.1B (3.77%)
FY2023 $14.7B (12.48%)
FY2022 $16.8B (7.07%)
FY2021 $18.1B (2.61%)
FY2020 $18.5B 3.32%
FY2019 $17.9B (7.37%)
FY2018 $19.4B (30.13%)
FY2017 $27.7B 34.01%
FY2016 $20.7B 252.13%

Quarterly newest first

Period Total debt Change
Jun 2026 $32.6B (4.23%)
Mar 2026 $34.0B 163.34%
Dec 2025 $12.9B (0.09%)
Sep 2025 $12.9B (3.69%)
42 more quarters

Against its own ten years

Low $5.9B High $27.7B
Ten-year median $17.9B
Current reading's percentile 18

Total debt against peers

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on ABT